Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Buy
92
AARD Quote, Financials, Valuation and Earnings
Last price:
$14.43
Seasonality move
:
--
Day range:
$14.31 - $16.00
52-week range:
$4.88 - $19.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.78x
Volume:
333.2K
Avg. volume:
190.7K
1-year change:
--
Market cap:
$339.9M
Revenue:
--
EPS (TTM):
-$2.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AARD
Aardvark Therapeutics, Inc.
|
-- | -$0.80 | -- | -108.23% | $32.44 |
|
EXAS
EXACT Sciences Corp.
|
$810.6M | $0.16 | 20.65% | -84.17% | $103.67 |
|
IMUX
Immunic, Inc.
|
-- | -$0.18 | -- | -63.39% | $5.38 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 64.56% | -3.9% | $224.89 |
|
MBX
MBX Biosciences, Inc.
|
-- | -$0.68 | -- | -47.08% | $58.63 |
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
-- | -$0.49 | -100% | -91.25% | $20.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AARD
Aardvark Therapeutics, Inc.
|
$15.61 | $32.44 | $339.9M | -- | $0.00 | 0% | -- |
|
EXAS
EXACT Sciences Corp.
|
$101.36 | $103.67 | $19.2B | -- | $0.00 | 0% | 6.17x |
|
IMUX
Immunic, Inc.
|
$0.66 | $5.38 | $78.9M | -- | $0.00 | 0% | -- |
|
INSM
Insmed, Inc.
|
$195.24 | $224.89 | $41.6B | -- | $0.00 | 0% | 83.09x |
|
MBX
MBX Biosciences, Inc.
|
$28.43 | $58.63 | $955.1M | -- | $0.00 | 0% | -- |
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
$1.26 | $20.00 | $7.9M | -- | $0.00 | 0% | 3.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AARD
Aardvark Therapeutics, Inc.
|
0.44% | 0.000 | 0.19% | 11.77x |
|
EXAS
EXACT Sciences Corp.
|
50.33% | 1.709 | 24.46% | 2.24x |
|
IMUX
Immunic, Inc.
|
7.01% | -0.188 | 0.91% | 1.17x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
MBX
MBX Biosciences, Inc.
|
0.16% | 1.240 | 0.11% | 32.47x |
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
-2.31% | 4.130 | 1.75% | 0.06x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AARD
Aardvark Therapeutics, Inc.
|
-$10K | -$17.7M | -43.07% | -43.34% | -- | -$18.5M |
|
EXAS
EXACT Sciences Corp.
|
$583.9M | $16.3M | -18.87% | -38% | 1.91% | $190M |
|
IMUX
Immunic, Inc.
|
-$40K | -$26M | -498.2% | -521.65% | -- | -$20.2M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
MBX
MBX Biosciences, Inc.
|
-$100K | -$23.9M | -29.32% | -29.36% | -- | -$21.9M |
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
-$22.2K | -$3.8M | -1563.18% | -1790.87% | -284.94% | -$1.8M |
Aardvark Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns AARD or EXAS?
EXACT Sciences Corp. has a net margin of -- compared to Aardvark Therapeutics, Inc.'s net margin of -2.3%. Aardvark Therapeutics, Inc.'s return on equity of -43.34% beat EXACT Sciences Corp.'s return on equity of -38%.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics, Inc.-- -$0.75 $122.9M EXASEXACT Sciences Corp.68.64% -$0.10 $5B -
What do Analysts Say About AARD or EXAS?
Aardvark Therapeutics, Inc. has a consensus price target of $32.44, signalling upside risk potential of 107.84%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $103.67 which suggests that it could grow by 2.28%. Given that Aardvark Therapeutics, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Aardvark Therapeutics, Inc. is more attractive than EXACT Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics, Inc.7 0 0 EXASEXACT Sciences Corp.3 18 0 -
Is AARD or EXAS More Risky?
Aardvark Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.
-
Which is a Better Dividend Stock AARD or EXAS?
Aardvark Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or EXAS?
Aardvark Therapeutics, Inc. quarterly revenues are --, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Aardvark Therapeutics, Inc.'s net income of -$16.3M is higher than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Aardvark Therapeutics, Inc.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics, Inc. is -- versus 6.17x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics, Inc.-- -- -- -$16.3M EXASEXACT Sciences Corp.6.17x -- $850.7M -$19.6M
-
Which has Higher Returns AARD or IMUX?
Immunic, Inc. has a net margin of -- compared to Aardvark Therapeutics, Inc.'s net margin of --. Aardvark Therapeutics, Inc.'s return on equity of -43.34% beat Immunic, Inc.'s return on equity of -521.65%.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics, Inc.-- -$0.75 $122.9M IMUXImmunic, Inc.-- -$0.13 $11.3M -
What do Analysts Say About AARD or IMUX?
Aardvark Therapeutics, Inc. has a consensus price target of $32.44, signalling upside risk potential of 107.84%. On the other hand Immunic, Inc. has an analysts' consensus of $5.38 which suggests that it could grow by 719.36%. Given that Immunic, Inc. has higher upside potential than Aardvark Therapeutics, Inc., analysts believe Immunic, Inc. is more attractive than Aardvark Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics, Inc.7 0 0 IMUXImmunic, Inc.9 0 0 -
Is AARD or IMUX More Risky?
Aardvark Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immunic, Inc. has a beta of 1.479, suggesting its more volatile than the S&P 500 by 47.918%.
-
Which is a Better Dividend Stock AARD or IMUX?
Aardvark Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics, Inc. pays -- of its earnings as a dividend. Immunic, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or IMUX?
Aardvark Therapeutics, Inc. quarterly revenues are --, which are smaller than Immunic, Inc. quarterly revenues of --. Aardvark Therapeutics, Inc.'s net income of -$16.3M is higher than Immunic, Inc.'s net income of -$25.6M. Notably, Aardvark Therapeutics, Inc.'s price-to-earnings ratio is -- while Immunic, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics, Inc. is -- versus -- for Immunic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics, Inc.-- -- -- -$16.3M IMUXImmunic, Inc.-- -- -- -$25.6M
-
Which has Higher Returns AARD or INSM?
Insmed, Inc. has a net margin of -- compared to Aardvark Therapeutics, Inc.'s net margin of -259.95%. Aardvark Therapeutics, Inc.'s return on equity of -43.34% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics, Inc.-- -$0.75 $122.9M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About AARD or INSM?
Aardvark Therapeutics, Inc. has a consensus price target of $32.44, signalling upside risk potential of 107.84%. On the other hand Insmed, Inc. has an analysts' consensus of $224.89 which suggests that it could grow by 15.19%. Given that Aardvark Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Aardvark Therapeutics, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics, Inc.7 0 0 INSMInsmed, Inc.16 1 0 -
Is AARD or INSM More Risky?
Aardvark Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock AARD or INSM?
Aardvark Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or INSM?
Aardvark Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Aardvark Therapeutics, Inc.'s net income of -$16.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Aardvark Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics, Inc. is -- versus 83.09x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics, Inc.-- -- -- -$16.3M INSMInsmed, Inc.83.09x -- $142.3M -$370M
-
Which has Higher Returns AARD or MBX?
MBX Biosciences, Inc. has a net margin of -- compared to Aardvark Therapeutics, Inc.'s net margin of --. Aardvark Therapeutics, Inc.'s return on equity of -43.34% beat MBX Biosciences, Inc.'s return on equity of -29.36%.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics, Inc.-- -$0.75 $122.9M MBXMBX Biosciences, Inc.-- -$0.63 $388.2M -
What do Analysts Say About AARD or MBX?
Aardvark Therapeutics, Inc. has a consensus price target of $32.44, signalling upside risk potential of 107.84%. On the other hand MBX Biosciences, Inc. has an analysts' consensus of $58.63 which suggests that it could grow by 106.21%. Given that Aardvark Therapeutics, Inc. has higher upside potential than MBX Biosciences, Inc., analysts believe Aardvark Therapeutics, Inc. is more attractive than MBX Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics, Inc.7 0 0 MBXMBX Biosciences, Inc.7 0 1 -
Is AARD or MBX More Risky?
Aardvark Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MBX Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AARD or MBX?
Aardvark Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MBX Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics, Inc. pays -- of its earnings as a dividend. MBX Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or MBX?
Aardvark Therapeutics, Inc. quarterly revenues are --, which are smaller than MBX Biosciences, Inc. quarterly revenues of --. Aardvark Therapeutics, Inc.'s net income of -$16.3M is higher than MBX Biosciences, Inc.'s net income of -$21.6M. Notably, Aardvark Therapeutics, Inc.'s price-to-earnings ratio is -- while MBX Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics, Inc. is -- versus -- for MBX Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics, Inc.-- -- -- -$16.3M MBXMBX Biosciences, Inc.-- -- -- -$21.6M
-
Which has Higher Returns AARD or SONN?
Sonnet BioTherapeutics Holdings, Inc. has a net margin of -- compared to Aardvark Therapeutics, Inc.'s net margin of -316.07%. Aardvark Therapeutics, Inc.'s return on equity of -43.34% beat Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -1790.87%.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics, Inc.-- -$0.75 $122.9M SONNSonnet BioTherapeutics Holdings, Inc.-- -$0.95 -$3M -
What do Analysts Say About AARD or SONN?
Aardvark Therapeutics, Inc. has a consensus price target of $32.44, signalling upside risk potential of 107.84%. On the other hand Sonnet BioTherapeutics Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 1487.3%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than Aardvark Therapeutics, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than Aardvark Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics, Inc.7 0 0 SONNSonnet BioTherapeutics Holdings, Inc.1 0 0 -
Is AARD or SONN More Risky?
Aardvark Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, suggesting its more volatile than the S&P 500 by 47.817%.
-
Which is a Better Dividend Stock AARD or SONN?
Aardvark Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sonnet BioTherapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics, Inc. pays -- of its earnings as a dividend. Sonnet BioTherapeutics Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or SONN?
Aardvark Therapeutics, Inc. quarterly revenues are --, which are smaller than Sonnet BioTherapeutics Holdings, Inc. quarterly revenues of --. Aardvark Therapeutics, Inc.'s net income of -$16.3M is lower than Sonnet BioTherapeutics Holdings, Inc.'s net income of -$3.8M. Notably, Aardvark Therapeutics, Inc.'s price-to-earnings ratio is -- while Sonnet BioTherapeutics Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics, Inc. is -- versus 3.33x for Sonnet BioTherapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics, Inc.-- -- -- -$16.3M SONNSonnet BioTherapeutics Holdings, Inc.3.33x -- -- -$3.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
54
SMX alert for Dec 12
SMX (Security Matters) Plc [SMX] is down 14.67% over the past day.
Buy
77
DHIL alert for Dec 12
Diamond Hill Investment Group, Inc. [DHIL] is down 0.54% over the past day.
Sell
28
OXM alert for Dec 12
Oxford Industries, Inc. [OXM] is up 9.32% over the past day.
